Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook. The shares fell anyway, with investors fixated on pricing pressure and the quality of the beat. Then, at a strategy day in London a few weeks ago, management said it aims to grow revenue through 2030 at roughly the pace of large drugmaker peers. Founded in 1923, the Danish company built its heritage in diabetes care. Today it makes Wegovy, Ozempic and a growing line of diabetes and obesity medicines, now joined by a Wegovy pill, and it sells in around 170 countries. Whether the sell-off went too far depends on what a company promising peer-level growth is worth, and on how quickly its newest products can carry the load.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.